A randomized controlled crossover trial recently published in the Lancet assessed the use of oral immunotherapy (OIT) for the treatment of peanut allergy in children 7 to 16 years of age. Participants were given peanut protein in increasing doses of 2-800 mg daily for 6 months. At the end of the study, researchers found that the participants who had undergone OIT had a median increase in peanut tolerance of 1345 mg. 54% tolerated 1400 mg (around ten peanuts) and 91% tolerated 800 mg of peanut protein. How often does oral immunotherapy come up in discussions with your patients? How comfortable are you discussing questions related to food allergies?
For additional information, please click The Lancet.
Image courtesy of [zole4]/FreeDigitalPhotos.net.